Bcl-2 Antibody
Code | Size | Price |
---|
PSI-3335-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-3335-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
Bcl-2 Antibody: Bcl-2, PPP1R50, Apoptosis regulator Bcl-2
Application Note:
WB: 1-2μg/mL; IHC-P: 2 μg/mL; IF: 10 μg/mL.
Antibody validated: Western Blot in human and mouse samples; Immunohistochemistry in human and mouse samples ; Immunofluorescence in human and mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human and mouse samples; Immunohistochemistry in human and mouse samples ; Immunofluorescence in human and mouse samples. All other applications and species not yet tested.
Background:
Bcl-2 Antibody: Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. Bcl-2 is the founding member of a family of over 20 proteins that are critical regulators of apoptosis. These can be divided into two classes: those that inhibit apoptosis and those that promote cell death. Bcl-2 is an inner mitochondrial membrane protein that inhibits apoptosis. It is thought to act by interacting with pro-apoptotic Bcl-2 family members such as Bak and Bad. Overexpression of Bcl-2 has been linked to human cancers such as B-cell lymphoma and prostate cancer.
Background References:
- Lockshin et al. Cell Death Differ. 2000; 7:2-7.
- Cory et al. Oncogene 2003; 22:8590-607.
- Heiser et al. Exp. Geron. 2004; 39:1125-35.
- Hockenbery et al. Nature 1990; 348:334-6.
Buffer:
Bcl-2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (100%), Rat: (100%), Chicken: (93%)
Immunogen:
Anti-Bcl-2 antibody (3335) was raised against a peptide corresponding to 15 amino acids near the amino terminus of human Bcl-2.
The immunogen is located within the first 50 amino acids of Bcl-2.
The immunogen is located within the first 50 amino acids of Bcl-2.
ISOFORMS:
Human Bcl-2 has 2 isoforms, including isoform 1 (239aa, 26kD), and isoform 2 (205aa, 22kD). Mouse Bcl-2 has 2 isoforms, including isoform 1 (236aa, 26kD), and isoform 2 (199aa, 22kD). Rat Bcl-2 has one isoform (236aa, 27kD). 3337 can detect all isoforms of human, mouse and rat
NCBI Gene ID #:
596
NCBI Official Name:
B-cell CLL/lymphoma 2
NCBI Official Symbol:
BCL2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 26kD
Observed: 26 kD
Observed: 26 kD
Protein Accession #:
AAH27258
Protein GI Number:
20072668
Purification:
Bcl-2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis,Autophagy,Cancer
Swissprot #:
P10415
User NOte:
Optimal dilutions for each application to be determined by the researcher.
VALIDATION:
Independent Antibody Validation in Cell lines (Figure 2) shows similar Bcl-2 expression profile in human and mouse cell lines detected by two independent anti-Bcl-2 antibodies that recognize different epitopes, 3335 against N-terminus domain and 3337 against central domain. Bcl-2 proteins are detected in several tested cell lines at different expression levels by the two independent antibodies.
Related Products
Product Name | Product Code | Supplier | Bcl-2 Peptide | PSI-3335P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|